Latest Headlines

31. Agora Open Science Trust Announces Nomination Of M4K2009 As Lead Development Candidate For Pediatric Brain Cancer Therapy 12/8/2025

    Agora Open Science Trust today announced the nomination of M4K2009 as the lead development candidate for its M4K Pharma program, which applies open science to drive the development of an affordable treatment for Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer.

32. AI-For-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab For Drug Discovery In Singapore 12/7/2025

    ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia.

33. Advanced Brain Imaging Reveals Promise Of New Drug For Parkinson's Disease 12/4/2025

    University of Queensland researchers have developed a promising new anti-inflammatory drug and, for the first time, used advanced imaging to watch its effects unfold inside the living brain, a breakthrough that could accelerate treatments for Parkinson’s disease.

34. Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone In Collaboration With Bristol Myers Squibb 12/3/2025

    Terray Therapeutics (www.terraytx.ai), a chemistry-first, AI-native biotech company, today announced the achievement of a discovery milestone in the company’s multi-target collaboration with Bristol Myers Squibb.

35. Galux And Celltrion Enter Strategic Partnership To Co-Develop Next-Generation Multispecific Antibodies For Autoimmune Diseases 12/2/2025

    Galux announced a joint collaboration with Celltrion, a leading biopharmaceutical company based in Incheon, to co-develop next-generation multispecific antibodies for autoimmune diseases.

36. U.S. FDA Grants Birchbiomed Orphan Drug Designation For FS2 In The Treatment Of Idiopathic Pulmonary Fibrosis 12/2/2025

    BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders and autoimmune therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary fibrosis (IPF).

37. Citizen Health Joins Forces With UCB To Accelerate Drug Development Across Epilepsy And Rare Diseases 12/2/2025

    Citizen Health today announced a new strategic partnership with UCB, a global biopharmaceutical leader in neurological and autoimmune research and development. The multi-year collaboration launches with a focus on epilepsy and five rare disease indications.

38. Curi Bio Secures $10M Series B To Scale Human-Relevant Preclinical Platforms And Advanced Data Analysis For Drug Discovery 12/2/2025

    Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10M Series B financing round.

39. Peapod Bio Inc. And Enamine Ltd. Announce Strategic Collaboration 12/2/2025

    Peapod Bio Inc., a leader in innovative assay development and high-throughput screening (HTS) solutions, today announced a strategic collaboration with Enamine, a global supplier of high-quality small molecule libraries.

40. Latus Bio Announces IND Clearance Of LTS-101 For CLN2 Disease And Receipt Of Fast Track, Orphan Drug, And Rare Pediatric Disease Designations 12/2/2025

    Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announces clearance by the U.S. Food and Drug Administration (FDA) of the Company’s Investigational New Drug (IND) application for LTS-101 - a gene therapy candidate that’s intended to treat the CNS manifestations of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.